Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:INSM News 18 December 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed shares closed Monday at $175.76, up 0.53%, then traded between $175.76 and $178.05 after hours. The stock joined the Nasdaq-100 effective Dec. 22, prompting index-related activity. No new company announcements appeared after the bell. Investors continued to weigh last week’s brensocatib CRSsNP trial failure.
23 December 2025
··
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed joined the Nasdaq-100 Index on December 22, 2025, boosting its stock visibility. Shares traded at $177.86, up 1.7%, after recent swings triggered by a failed Phase 2b trial for brensocatib in chronic rhinosinusitis, which led the company to end that program. Insmed also acquired INS1148, a Phase 2–ready monoclonal antibody, for $40 million upfront.
22 December 2025
·
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed will join the Nasdaq-100 before markets open Monday, December 22, 2025. Shares fell 11% last week after the company halted development of brensocatib in chronic rhinosinusitis without nasal polyps following a failed Phase 2b trial. The stock last traded near $174.84. Holiday trading may affect liquidity and volatility.
21 December 2025
·
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed shares closed Friday, Dec. 19, 2025, at $174.84, up nearly 5%, after a volatile week triggered by a failed Phase 2b trial for brensocatib in CRSsNP. The company said it would discontinue that program. Shares held steady in after-hours trading. Insmed also announced the acquisition of INS1148, a Phase 2–ready monoclonal antibody.
20 December 2025
·
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.
19 December 2025
·
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC+1 Insmed stock was trading around $166.75 in the afternoon snapshot available from market data, down about 16% on the day, after touching an intraday low of $158.06 and high of $173.99. What happened to INSM stock on December 18, 2025 The selloff traces back to Insmed’s disclosure that its Phase
18 December 2025
···

Stock Market Today

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

8 February 2026
GigaDevice Semiconductor’s Class A shares closed at 276.17 yuan in Shanghai, down 0.6% Friday. The company faces a Feb. 11 shareholder vote on related-party transaction limits and an overseas auditor. Investors are watching for fallout from the global memory-chip shortage, which has pushed prices higher across the supply chain. GigaDevice’s shares have nearly doubled over the past year.
Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

8 February 2026
Astera Labs shares jumped 18.9% to $169.85 Friday, trading as high as $170.01 on volume of 7.3 million. The move followed Amazon’s AI spending forecast and a nearly 6% gain in the PHLX Semiconductor Index. Astera reports fourth-quarter results Tuesday after market close, with revenue guidance at $245–$253 million.
Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

8 February 2026
Sungrow closed at 144.50 yuan, down 1.03%, after stating it has no plans in the commercial space sector. Mainland China trading resumes Monday, with Spring Festival closures set for Feb. 15–23. Major funds were net sellers of 5.46 billion yuan on Feb. 6. The Shenzhen-listed solar firm remains under scrutiny as investors await further filings before the holiday.
MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

8 February 2026
Monolithic Power Systems shares surged 6.4% to $1,229.82 Friday, hitting a new 52-week high after raising its dividend to $2.00 and forecasting first-quarter revenue of $770 million to $790 million. CEO Michael Hsing filed a Rule 144 notice for 3,082 shares. CFO Bernie Blegen will retire after the 2025 annual report, with Rob Dean named interim CFO. Fourth-quarter revenue rose 20.8% to $751.2 million.
Go toTop